摘要
类风湿关节炎(RA)是以滑膜炎及自身抗体分泌为特点的慢性系统性炎症性自身免疫性疾病,炎症细胞因子白介素-6(IL-6)的过量表达在RA发病与进展过程中具有重要作用。托珠单抗是首个人源化IL-6受体单克隆抗体,可阻断IL-6生物学活性,明显缓解RA的临床症状,有效防止关节破坏。本文综述托珠单抗在RA临床治疗中的研究进展。
Rheumatoid arthritis （RA） is a chronic systemic inflammatory autoimmune disease characterized by persistent synovitis and autoantibodies secretion. Over-expression of interleukin-6 （IL-6） has been shown to play an important role in the pathogenesis and progression of RA. As the first humanized IL-6 receptor monoclonal antibody, tolicizumab can block biological actions of IL-6. So tolicizumab shows effects not only on improving symptoms of RA but also on preventing joint destruction of RA. The review summarizes research advance of therapy of tolicizumab in rheumatoid arthritis.
出处
《世界临床药物》
CAS
2014年第9期523-526,546,共5页
World Clinical Drug
